General MedicationsORALStandard

DARUNAVIR AND RITONAVIR

Standard Dose

400MG/50MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: PRIORITY Marketing status: Prescription

Summary

Approval overview DARUNAVIR AND RITONAVIR is listed in Drugs@FDA under application 209847 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient DARUNAVIR AND RITONAVIR Form and strength TABLET; ORAL - 400MG/50MG Sponsor MYLAN PHARMS INC Submission history Latest submission status date: 2023-12-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview DARUNAVIR AND RITONAVIR is listed in Drugs@FDA under application 209847 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient DARUNAVIR AND RITONAVIR Form and strength TABLET; ORAL - 400MG/50MG Sponsor MYLAN PHARMS INC Submission history Latest submission status date: 2023-12-22 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Prescription
• Review priority: PRIORITY

Interaction Notes

No interaction notes stored yet.